November 2026 Webinar

Jason Gotlib

Dr. Gotlib is Professor of Medicine in the Division of Hematology at the Stanford University School of Medicine / Stanford Cancer Institute. His research focus is clinical and translational evaluation of novel therapies for myeloproliferative neoplasms, with a focus on KIT inhibitors for systemic mastocytosis (SM). Dr. Gotlib has authored more than 250 research articles, chapters, and reviews that have been published in journals such as Blood, Journal of Clinical Oncology, Nature Medicine, and The New England Journal of Medicine. He is Vice-Chair of the NCCN Guidelines Committee on Myeloproliferative Neoplasms, and chaired the NCCN guideline development for SM. He led the clinical development of midostaurin and avapritinib for patients with advanced SM, as well as response criteria for these diseases which are used by regulatory agencies for drug approval. Dr. Gotlib was awarded the European Competence Network on Mastocytosis (ECNM) Medal as Researcher of the Year in 2019 for the development of KIT-targeting therapies in advanced SM. He currently serves as President of the American Initiative in Mast Cell Diseases (AIM). Dr. Gotlib enjoys landscape photography in his spare time.

Andreas Reiter

Dr Andreas Reiter is an Associate Professor and Consultant of Hematology and Oncology at the Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Germany. Dr Reiter’s main research focus lies on pathogenesis, diagnosis and treatment of myeloproliferative neoplasms (MPN). Since 1992, he has been involved in translational research and numerous clinical trials, most recently particularly focusing on treatment of classic MPN and translational research for a better understanding of pathogenesis, diagnosis and treatment of eosinophilia-associated disorders and systemic mastocytosis. Dr Reiter has established a “German Registry for Disorders of Eosinophils and Mast Cells (GREM)”.

Brent Tan

Dr. Brent Tan received a B.S. from University of California, Los Angeles, in biochemistry, an M.D. from the University of California, Los Angeles, and a PhD in molecular biology from the University of California, Los Angeles. He trained as a resident in anatomic pathology and fellow in hematopathology at Stanford, followed by postdoctoral research in the laboratory of Dr. Irving Weissman at Stanford studying cancer stem cells. His current interests include myeloid neoplasms, T cell lymphomas, molecular hematopathology, digital pathology, and laboratory information systems. He is boarded in anatomic pathology, hematopathology, and clinical informatics.

Simin Zhang

Francesca Levi-Schaffer

Francesca Levi-Schaffer is a Professor in the Institute for Drug Research, School of Pharmacy, Faculty of Medicine of The Hebrew University of Jerusalem. She holds the Isaac and Myrna Kaye Chair in Immunopharmacology. She completed her PharmD at the University of Milano, PhD in Immunology at the Weizmann Institute, and post-doctorate at Harvard Medical School. Prof. Levi-Schaffer has published 184 articles in peer-reviewed journals, 106 reviews and editorials and 27 book chapters and has three patents and three provisional patents. Her expertise is in immunopharmacology of allergy focusing on mast cells and eosinophils, their activating and inhibitory receptors, and their cross-talk for a better prophylaxis/treatment of allergic diseases.